AstraZeneca makes $1B deal for Gracell and its cell therapies, adding to China ties
AstraZeneca will pay $1 billion to buy China-US cell therapy company Gracell Biotechnologies, adding to a rush of deals that have been announced at the end of 2023 to shore up big pharma pipelines.
For AstraZeneca, the latest acquisition marks two key moves: gaining a foothold in the rising tide of autoimmune cell therapies and furthering its place in the Chinese biotech ecosystem, which CEO Pascal Soriot has previously said was on his shopping list.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.